Aldeyra Therapeutics
ALDX
28 hedge funds and large institutions have $18.2M invested in Aldeyra Therapeutics in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 0 closing their positions.
33% more funds holding
Funds holding: 21 → 28 (+7)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
39% less capital invested
Capital invested by funds: $30M → $18.2M (-$11.8M)
Top Buyers
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$847K |
| 2 |
CL
Croft-Leominster
Baltimore,
Maryland
|
+$81.7K |
| 3 |
FMA
FNY Managed Accounts
New York
|
+$31.2K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13K |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$1.05M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$133K |
| 3 |
Millennium Management
New York
|
-$48K |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$23.2K |
| 5 |
Morgan Stanley
New York
|
-$17.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Walleye Trading
New York
| $1K | +$1.44K | +300 | New |
|
27
Geode Capital Management
Boston,
Massachusetts
| $98 | +$4.8K | +1,000 | +4% |
|
28
Citigroup
New York
| – | +$19 | +4 | New |
|
ALDX Hedge Fund Activity: Q1 2016 in Review
28 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q1 2016, worth a combined $18.2M — down 39% from $30M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ALDX positions and 0 closed out — a net gain of 7 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $847K. The largest seller was Deerfield Management, cutting an estimated $1.05M.
- 28 institutional investors held Aldeyra Therapeutics (ALDX) as of Q1 2016, up from 21 in Q4 2015.
- Funds reported $18.2M of Aldeyra Therapeutics stock for Q1 2016, down 39% quarter-over-quarter.
- 7 funds opened new Aldeyra Therapeutics positions in Q1 2016 and 0 closed out, a net change of +7 holders.
- The largest Aldeyra Therapeutics buyer in Q1 2016 was DAFNA Capital Management, an estimated $847K added.
- The largest Aldeyra Therapeutics seller in Q1 2016 was Deerfield Management, an estimated $1.05M sold.
Based on aggregated 13F filings for Q1 2016.